Comment le Ki-67 affecte-t-il le suivi du traitement ?
Le suivi du Ki-67 peut aider à évaluer la réponse au traitement et ajuster les stratégies.
SuiviRéponse au traitementAntigène Ki-67
#5
Les traitements sont-ils différents selon le type de cancer et le Ki-67 ?
Oui, les traitements peuvent varier selon le type de cancer et le niveau de Ki-67.
Type de cancerTraitementAntigène Ki-67
Complications
5
#1
Quelles complications peuvent survenir avec un score Ki-67 élevé ?
Un score élevé peut entraîner des complications comme des métastases et une récidive.
ComplicationsMétastasesRécidive
#2
Le Ki-67 est-il lié à des complications spécifiques ?
Oui, un score élevé est souvent associé à des complications plus graves dans le cancer.
Antigène Ki-67ComplicationsCancer
#3
Comment le Ki-67 affecte-t-il le pronostic des complications ?
Un score élevé indique un pronostic défavorable, augmentant le risque de complications.
PronosticComplicationsAntigène Ki-67
#4
Les complications varient-elles selon le type de cancer et le Ki-67 ?
Oui, les complications peuvent varier selon le type de cancer et le niveau de Ki-67.
Type de cancerComplicationsAntigène Ki-67
#5
Le suivi régulier peut-il réduire les complications liées au Ki-67 ?
Oui, un suivi régulier permet de détecter et de traiter rapidement les complications.
Suivi régulierComplicationsAntigène Ki-67
Facteurs de risque
5
#1
Quels sont les facteurs de risque associés à un score Ki-67 élevé ?
Les facteurs incluent l'âge, les antécédents familiaux et certains modes de vie.
Facteurs de risqueAntécédents familiauxCancer
#2
Le tabagisme influence-t-il le Ki-67 ?
Oui, le tabagisme est un facteur de risque pour plusieurs cancers, affectant le Ki-67.
TabagismeAntigène Ki-67Cancer
#3
L'alimentation joue-t-elle un rôle dans le Ki-67 ?
Une alimentation riche en graisses et en sucres peut augmenter le risque de cancer.
AlimentationFacteurs de risqueAntigène Ki-67
#4
Les facteurs génétiques affectent-ils le Ki-67 ?
Oui, des mutations génétiques peuvent influencer la prolifération cellulaire et le Ki-67.
Facteurs génétiquesAntigène Ki-67Cancer
#5
Le stress a-t-il un impact sur le Ki-67 ?
Le stress chronique peut affecter le système immunitaire, influençant le cancer et le Ki-67.
StressAntigène Ki-67Cancer
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Antigène KI-67 : Questions médicales les plus fréquentes",
"headline": "Antigène KI-67 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Antigène KI-67 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-03-01",
"dateModified": "2025-02-24",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Antigène KI-67"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Marqueurs biologiques tumoraux",
"url": "https://questionsmedicales.fr/mesh/D014408",
"about": {
"@type": "MedicalCondition",
"name": "Marqueurs biologiques tumoraux",
"code": {
"@type": "MedicalCode",
"code": "D014408",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.101.140"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Antigène KI-67",
"alternateName": "Ki-67 Antigen",
"code": {
"@type": "MedicalCode",
"code": "D019394",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Aleksandra Piotrowska",
"url": "https://questionsmedicales.fr/author/Aleksandra%20Piotrowska",
"affiliation": {
"@type": "Organization",
"name": "Department of Human Morphology and Embryology, Division of Histology and Embryology, Wroclaw Medical University, Wroclaw, Poland."
}
},
{
"@type": "Person",
"name": "Piotr Dziegiel",
"url": "https://questionsmedicales.fr/author/Piotr%20Dziegiel",
"affiliation": {
"@type": "Organization",
"name": "Department of Human Morphology and Embryology, Division of Histology and Embryology, Wroclaw Medical University, Wroclaw, Poland."
}
},
{
"@type": "Person",
"name": "Giuseppe Pelosi",
"url": "https://questionsmedicales.fr/author/Giuseppe%20Pelosi",
"affiliation": {
"@type": "Organization",
"name": "Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy."
}
},
{
"@type": "Person",
"name": "William C Earnshaw",
"url": "https://questionsmedicales.fr/author/William%20C%20Earnshaw",
"affiliation": {
"@type": "Organization",
"name": "Wellcome Centre for Cell Biology, University of Edinburgh, ICB, Michael Swann Building, King's Buildings, Max Born Crescent, Edinburgh EH9 3BF, UK."
}
},
{
"@type": "Person",
"name": "Francesca Di Rosa",
"url": "https://questionsmedicales.fr/author/Francesca%20Di%20Rosa",
"affiliation": {
"@type": "Organization",
"name": "Institute of Molecular Biology and Pathology, National Research Council of Italy (CNR), Rome, Italy."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Classification of Local Recurrence After Nipple-Sparing Mastectomy Based on Location: The Features of Nipple-Areolar Recurrence Differ from Those of Other Local Recurrences.",
"datePublished": "2022-11-13",
"url": "https://questionsmedicales.fr/article/36371582",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1245/s10434-022-12760-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "Feasibility of local therapy for recurrent pancreatic cancer.",
"datePublished": "2022-05-24",
"url": "https://questionsmedicales.fr/article/35641368",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.pan.2022.05.004"
}
},
{
"@type": "ScholarlyArticle",
"name": "Ultrasound Assessment of Skin Tumors Local Recurrence.",
"datePublished": "2023-05-17",
"url": "https://questionsmedicales.fr/article/37195073",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/jum.16255"
}
},
{
"@type": "ScholarlyArticle",
"name": "Pathological determinants of outcome following resection of locally advanced or locally recurrent rectal cancer.",
"datePublished": "2023-06-26",
"url": "https://questionsmedicales.fr/article/37442715",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejso.2023.06.023"
}
},
{
"@type": "ScholarlyArticle",
"name": "Intraparenchymal metastases as a cause for local recurrence of pancreatic cancer.",
"datePublished": "2022-11-21",
"url": "https://questionsmedicales.fr/article/36371607",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/his.14839"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Marqueurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D015415"
},
{
"@type": "ListItem",
"position": 4,
"name": "Marqueurs biologiques tumoraux",
"item": "https://questionsmedicales.fr/mesh/D014408"
},
{
"@type": "ListItem",
"position": 5,
"name": "Antigène KI-67",
"item": "https://questionsmedicales.fr/mesh/D019394"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Antigène KI-67 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Antigène KI-67",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-03",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Antigène KI-67",
"description": "Comment le Ki-67 est-il utilisé dans le diagnostic du cancer ?\nQuel type d'échantillon est nécessaire pour le test Ki-67 ?\nQuelle est l'importance du score Ki-67 ?\nLe Ki-67 est-il spécifique à certains types de cancer ?\nComment le Ki-67 est-il mesuré ?",
"url": "https://questionsmedicales.fr/mesh/D019394?mesh_terms=Neoplasm+Recurrence,+Local#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Antigène KI-67",
"description": "Quels symptômes peuvent indiquer un cancer avec un score Ki-67 élevé ?\nLe Ki-67 influence-t-il les symptômes du cancer ?\nLes symptômes sont-ils liés à la prolifération cellulaire ?\nUn score Ki-67 bas signifie-t-il moins de symptômes ?\nLes symptômes varient-ils selon le type de cancer et le Ki-67 ?",
"url": "https://questionsmedicales.fr/mesh/D019394?mesh_terms=Neoplasm+Recurrence,+Local#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Antigène KI-67",
"description": "Peut-on prévenir un cancer associé à un score Ki-67 élevé ?\nY a-t-il des mesures préventives spécifiques pour le cancer ?\nLe Ki-67 peut-il être un indicateur de prévention ?\nComment le dépistage précoce aide-t-il avec le Ki-67 ?\nLes habitudes alimentaires influencent-elles le Ki-67 ?",
"url": "https://questionsmedicales.fr/mesh/D019394?mesh_terms=Neoplasm+Recurrence,+Local#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Antigène KI-67",
"description": "Le Ki-67 influence-t-il le choix du traitement ?\nQuels traitements sont associés à un score Ki-67 élevé ?\nLe Ki-67 est-il un facteur dans les traitements hormonaux ?\nComment le Ki-67 affecte-t-il le suivi du traitement ?\nLes traitements sont-ils différents selon le type de cancer et le Ki-67 ?",
"url": "https://questionsmedicales.fr/mesh/D019394?mesh_terms=Neoplasm+Recurrence,+Local#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Antigène KI-67",
"description": "Quelles complications peuvent survenir avec un score Ki-67 élevé ?\nLe Ki-67 est-il lié à des complications spécifiques ?\nComment le Ki-67 affecte-t-il le pronostic des complications ?\nLes complications varient-elles selon le type de cancer et le Ki-67 ?\nLe suivi régulier peut-il réduire les complications liées au Ki-67 ?",
"url": "https://questionsmedicales.fr/mesh/D019394?mesh_terms=Neoplasm+Recurrence,+Local#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Antigène KI-67",
"description": "Quels sont les facteurs de risque associés à un score Ki-67 élevé ?\nLe tabagisme influence-t-il le Ki-67 ?\nL'alimentation joue-t-elle un rôle dans le Ki-67 ?\nLes facteurs génétiques affectent-ils le Ki-67 ?\nLe stress a-t-il un impact sur le Ki-67 ?",
"url": "https://questionsmedicales.fr/mesh/D019394?mesh_terms=Neoplasm+Recurrence,+Local#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment le Ki-67 est-il utilisé dans le diagnostic du cancer ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le Ki-67 est mesuré pour évaluer le taux de prolifération cellulaire dans les tumeurs."
}
},
{
"@type": "Question",
"name": "Quel type d'échantillon est nécessaire pour le test Ki-67 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un échantillon de tissu tumoral est nécessaire, généralement obtenu par biopsie."
}
},
{
"@type": "Question",
"name": "Quelle est l'importance du score Ki-67 ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un score élevé indique une prolifération rapide, souvent associé à un pronostic défavorable."
}
},
{
"@type": "Question",
"name": "Le Ki-67 est-il spécifique à certains types de cancer ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, il est souvent utilisé dans les cancers du sein, de la prostate et lymphomes."
}
},
{
"@type": "Question",
"name": "Comment le Ki-67 est-il mesuré ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est mesuré par immunohistochimie, une technique de coloration des tissus."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un cancer avec un score Ki-67 élevé ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes varient, mais peuvent inclure fatigue, perte de poids et douleurs."
}
},
{
"@type": "Question",
"name": "Le Ki-67 influence-t-il les symptômes du cancer ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, le Ki-67 ne cause pas de symptômes, mais indique la gravité de la maladie."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils liés à la prolifération cellulaire ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une prolifération rapide peut entraîner des symptômes plus graves et avancés."
}
},
{
"@type": "Question",
"name": "Un score Ki-67 bas signifie-t-il moins de symptômes ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Pas nécessairement, mais un score bas est souvent associé à une maladie moins agressive."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type de cancer et le Ki-67 ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes peuvent varier selon le type de cancer et le niveau de prolifération."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir un cancer associé à un score Ki-67 élevé ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention passe par un mode de vie sain, mais le Ki-67 ne peut pas être prévenu."
}
},
{
"@type": "Question",
"name": "Y a-t-il des mesures préventives spécifiques pour le cancer ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, dépistage régulier et adoption de comportements sains peuvent réduire les risques."
}
},
{
"@type": "Question",
"name": "Le Ki-67 peut-il être un indicateur de prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, le Ki-67 est un marqueur de prolifération, pas un indicateur de prévention."
}
},
{
"@type": "Question",
"name": "Comment le dépistage précoce aide-t-il avec le Ki-67 ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le dépistage précoce permet de détecter des cancers à un stade où le Ki-67 est plus bas."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires influencent-elles le Ki-67 ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut réduire le risque de cancer, mais n'affecte pas directement le Ki-67."
}
},
{
"@type": "Question",
"name": "Le Ki-67 influence-t-il le choix du traitement ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un score élevé peut conduire à des traitements plus agressifs comme la chimiothérapie."
}
},
{
"@type": "Question",
"name": "Quels traitements sont associés à un score Ki-67 élevé ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Chimiothérapie, radiothérapie et thérapies ciblées sont souvent envisagées."
}
},
{
"@type": "Question",
"name": "Le Ki-67 est-il un facteur dans les traitements hormonaux ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, dans les cancers hormonodépendants, un score élevé peut influencer le traitement."
}
},
{
"@type": "Question",
"name": "Comment le Ki-67 affecte-t-il le suivi du traitement ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le suivi du Ki-67 peut aider à évaluer la réponse au traitement et ajuster les stratégies."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils différents selon le type de cancer et le Ki-67 ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent varier selon le type de cancer et le niveau de Ki-67."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec un score Ki-67 élevé ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un score élevé peut entraîner des complications comme des métastases et une récidive."
}
},
{
"@type": "Question",
"name": "Le Ki-67 est-il lié à des complications spécifiques ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un score élevé est souvent associé à des complications plus graves dans le cancer."
}
},
{
"@type": "Question",
"name": "Comment le Ki-67 affecte-t-il le pronostic des complications ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un score élevé indique un pronostic défavorable, augmentant le risque de complications."
}
},
{
"@type": "Question",
"name": "Les complications varient-elles selon le type de cancer et le Ki-67 ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications peuvent varier selon le type de cancer et le niveau de Ki-67."
}
},
{
"@type": "Question",
"name": "Le suivi régulier peut-il réduire les complications liées au Ki-67 ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi régulier permet de détecter et de traiter rapidement les complications."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque associés à un score Ki-67 élevé ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, les antécédents familiaux et certains modes de vie."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il le Ki-67 ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est un facteur de risque pour plusieurs cancers, affectant le Ki-67."
}
},
{
"@type": "Question",
"name": "L'alimentation joue-t-elle un rôle dans le Ki-67 ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation riche en graisses et en sucres peut augmenter le risque de cancer."
}
},
{
"@type": "Question",
"name": "Les facteurs génétiques affectent-ils le Ki-67 ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mutations génétiques peuvent influencer la prolifération cellulaire et le Ki-67."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur le Ki-67 ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le stress chronique peut affecter le système immunitaire, influençant le cancer et le Ki-67."
}
}
]
}
]
}
Immunosurveillance Laboratory, The Francis Crick Institute, London, United Kingdom.
Peter Gorer Department of Immunobiology, King's College London, London, United Kingdom.
National Institute for Health Research (NIHR) Biomedical Research Center (BRC), Guy's and St Thomas' NHS Foundation Trust and King's College London, London, United Kingdom.
Little information is available about the clinical and pathologic characteristics of local recurrence (LR) after nipple-sparing mastectomy according to the locations of LR....
This study classified 99 patients into the following two groups according to the location of LR after nipple-sparing mastectomy: nipple-areolar recurrence (NAR) group and other locations of LR (oLR) g...
For about half of the patients (44.4 %) with NAR, the primary cancer was estrogen receptor (ER)-negative and human epidermal growth factor receptor 2 (HER2)-positive. Conversely, in most of the patien...
This multi-institutional retrospective study demonstrated that the features of NAR, such as the characteristics of the primary and recurrent tumors and the prognostic factors after LR resection, were ...
Despite advances in perioperative management, recurrence after curative pancreatectomy is a critical issue in the treatment of pancreatic ductal adenocarcinoma (PDAC). The significance of local therap...
We reviewed the medical records of patients with PDAC who underwent curative resection at our institution between January 2009 and December 2019. We examined the patterns of relapse and assessed the c...
A total of 246 patients with PDAC who underwent R0 or R1 resection were included in this study. The 3-year overall survival (OS) rate was 39.8%, and the 1-year recurrence-free survival rate was 51.2% ...
Our results suggest that a multimodal approach may improve the clinical outcomes of patients with recurrent PDAC....
Skin cancer may recur at or around the surgical site despite wide excisions. Prompt clinical and sonographic detection of local recurrence is important since subjects with relapsing melanomas or nonme...
Pathological factors that influence and predict survival following pelvic exenteration (PE) for locally advanced (LARC) or locally recurrent rectal cancer (LRRC), especially LRRC, remain poorly unders...
A retrospective cohort study was performed for all patients undergoing a curative PE for LARC or LRRC between 2008 and 2021 at a tertiary referral UK specialist colorectal hospital. Cox regression ana...
388 patients were included in the analysis with 256 resections for LARC and 132 for LRRC. 62.4% of patients were male with a median age of 59 years (IQR 49-67). 247 (64%) partial pelvic exenterations ...
A positive resection margin and poorly differentiated tumours are significant negative prognostic markers for survival and recurrence in LARC. The results of this study support the need to look for al...
Using CODA, a technique for three-dimensional reconstruction of large tissues, Kiemen et al. report observation of a microscopic focus of pancreatic cancer found in the vasculature of grossly normal h...
The initial approach to the treatment of desmoid tumors has changed from surgical resection to watchful waiting. However, surgery is still sometimes considered for some patients, and it is likely that...
We sought to explore whether a combined molecular and clinical prognostic model for relapse in patients with desmoid tumors treated with surgery would allow us to identify patients who might do well w...
This was a retrospective, single-center study of 107 patients with desmoid tumors who were surgically treated between January 1980 and December 2015, with a median follow-up of 106 months (range 7 to ...
The multivariable analysis showed that S45F mutations (hazard ratio 5.25 [95% confidence interval 2.27 to 12.15]; p < 0.001) and tumor in the extremities (HR 3.15 [95% CI 1.35 to 7.33]; p = 0.008) wer...
CTNNB1 S45F mutations combined with other clinical variables are a potential prognostic biomarker associated with the risk of relapse in patients with desmoid tumors. The developed nomogram is simple ...
Level III, therapeutic study....
A first local recurrence is common after resection or radiotherapy for brain metastasis (BM). However, patients with BMs can develop multiple local recurrences over time. Published data on second loca...
Patients were identified from a database at Brigham and Women's Hospital in Boston. Hazard ratios and 95% confidence intervals for predictors of a second local recurrence were computed using a Cox pro...
Of 170 identified surgically treated first locally recurrent lesions, 74 (43.5%) progressed to second locally recurrent lesions at a median of 7 months after craniotomy. Subtotal resection of the firs...
A second local recurrence occurred after 43.5% of craniotomies for first recurrent lesions. Subtotal resection and infratentorial location were the strongest risk factors for worse second local recurr...
The current study was undertaken to provide more detailed prognostic models for early prediction of local recurrences and local recurrence free survival (RFS) using different radiologic and pathologic...
One hundred patients with locally advanced rectal carcinomas decided to receive neoadjuvant CRT were retrospectively recruited, Hazard ratios (HR) were determined in the two cox regression models and ...
HR of 1st group of models: T+N, T+N+G, T+N+G+S, T+N+G+S+PNI, and T+N+G+S+PNI+R were summated and categorized into scores, these scores were significantly correlated with the risk of recurrence (Somer'...
We propose that the addition of biologic factors to staging of rectal cancer provide precise stratification and association with local recurrences in patients received preoperative CRT....
This study aims to identify prognostic factors and define the best extent of surgery for optimizing treatment of local recurrence (LR) following colorectal cancer (CRC)....
An institutional database of consecutive patients who underwent radical resection (R0/R1) of LR following CRC was analyzed prospectively from 2010 to 2021 at one tertiary cancer center....
In this study, 75 patients were included with LR following CRC and analyzed. Patients were categorized as compartmental resections (CompRe) (n = 47) if all adjacent organs were systematically removed,...
Complete compartmental surgery is safe and improves local control. Optimal LR resection needs to remove all contiguous organs, with or without tumor involvement....
RET-fused mesenchymal neoplasms mostly affect the soft tissue of paediatric patients. Given their responsiveness to selective RET inhibitors, it remains critical to identify those extraordinary cases ...
Clinicopathological features were assessed and partner agnostic targeted next-generation sequencing on clinically validated platforms were performed. The patients were 18, 53, and 55 years old and inc...
Our study expands the clinicopathological and genetic spectrum of mesenchymal neoplasms associated with RET fusions....
